These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19282465)

  • 1. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone.
    Løvås K; Gjesdal CG; Christensen M; Wolff AB; Almås B; Svartberg J; Fougner KJ; Syversen U; Bollerslev J; Falch JA; Hunt PJ; Chatterjee VK; Husebye ES
    Eur J Endocrinol; 2009 Jun; 160(6):993-1002. PubMed ID: 19282465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
    Koetz KR; Ventz M; Diederich S; Quinkler M
    J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density is reduced in female but not male subjects with Addison's disease.
    Florkowski CM; Holmes SJ; Elliot JR; Donald RA; Espiner EA
    N Z Med J; 1994 Feb; 107(972):52-3. PubMed ID: 8115069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy.
    Camozzi V; Betterle C; Frigo AC; Zaccariotto V; Zaninotto M; De Caneva E; Lucato P; Gomiero W; Garelli S; Sabbadin C; Salvà M; Costa MD; Boscaro M; Luisetto G
    Endocrine; 2018 Feb; 59(2):319-329. PubMed ID: 28795340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BclI polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy.
    Koetz KR; van Rossum EF; Ventz M; Diederich S; Quinkler M
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):831-7. PubMed ID: 23134110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency].
    Fichna M; Gryczyńska M; Sowińska A; Sowiński J
    Przegl Lek; 2011; 68(2):96-102. PubMed ID: 21751518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
    Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy.
    Zimmermann A; Sido PG; Schulze E; Al Khzouz C; Lazea C; Coldea C; Weber MM
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):477-84. PubMed ID: 19170706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density in patients with treated Addison's disease.
    Braatvedt GD; Joyce M; Evans M; Clearwater J; Reid IR
    Osteoporos Int; 1999; 10(6):435-40. PubMed ID: 10663342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of corticosteroid replacement therapy and its effect on bones in Addison's disease].
    Heureux F; Maiter D; Boutsen Y; Devogelaer JP; Jamart J; Donckier J
    Ann Endocrinol (Paris); 2000 Sep; 61(3):179-83. PubMed ID: 10970940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.
    Schulz J; Frey KR; Cooper MS; Zopf K; Ventz M; Diederich S; Quinkler M
    Eur J Endocrinol; 2016 Apr; 174(4):531-8. PubMed ID: 26811406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
    Oksnes M; Björnsdottir S; Isaksson M; Methlie P; Carlsen S; Nilsen RM; Broman JE; Triebner K; Kämpe O; Hulting AL; Bensing S; Husebye ES; Løvås K
    J Clin Endocrinol Metab; 2014 May; 99(5):1665-74. PubMed ID: 24517155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BClI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison's disease.
    Giordano R; Marzotti S; Berardelli R; Karamouzis I; Brozzetti A; D'Angelo V; Mengozzi G; Mandrile G; Giachino D; Migliaretti G; Bini V; Falorni A; Ghigo E; Arvat E
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):863-70. PubMed ID: 22587831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GDF15 Is Elevated in Conditions of Glucocorticoid Deficiency and Is Modulated by Glucocorticoid Replacement.
    Melvin A; Chantzichristos D; Kyle CJ; Mackenzie SD; Walker BR; Johannsson G; Stimson RH; O'Rahilly S
    J Clin Endocrinol Metab; 2020 May; 105(5):1427-34. PubMed ID: 31853550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Introduction: Patients with primary adrenal insufficiency receive long - term glucocorticoid replacement therapy, which may cause osteoporosis].
    Vaňuga P; Ságová I
    Vnitr Lek; 2021; 67(5):264-269. PubMed ID: 35459392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of bone mineral density in patients with Addison's disease and isolated ACTH deficiency treated with glucocorticoid.
    Chikada N; Imaki T; Hotta M; Sato K; Takano K
    Endocr J; 2004 Jun; 51(3):355-60. PubMed ID: 15256782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of glucocorticoid receptor polymorphisms in relation to metabolic parameters in Addison's disease.
    Ross IL; Levitt NS; Van der Merwe L; Schatz DA; Johannsson G; Dandara C; Pillay TS; Blom DJ
    Eur J Endocrinol; 2013 Mar; 168(3):403-12. PubMed ID: 23239757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone density and turnover in Addison's disease: effect of glucocorticoid treatment.
    Valero MA; Leon M; Ruiz Valdepeñas MP; Larrodera L; Lopez MB; Papapietro K; Jara A; Hawkins F
    Bone Miner; 1994 Jul; 26(1):9-17. PubMed ID: 7950508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of bone mineral density in Addison's disease.
    Jódar E; Valdepeñas MP; Martinez G; Jara A; Hawkins F
    Clin Endocrinol (Oxf); 2003 May; 58(5):617-20. PubMed ID: 12699444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.
    Gagliardi L; Nenke MA; Thynne TR; von der Borch J; Rankin WA; Henley DE; Sorbello J; Inder WJ; Torpy DJ
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4149-57. PubMed ID: 25127090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.